HCP1803-3

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

160 competitors in Hypertension

#DrugCompanyPhaseTrials

1

Foundayo

Eli Lilly

Phase 3

32

Nitrostat

VViatris Specialty LLC

Phase 3

53

Baxfendy

AstraZeneca

Phase 3

34

HCP1803-3

Hanmi Pharmaceutical Company Limited

Phase 3

15

SGLT2

PProf. Dr. med. Ingo Eitel

Phase 3

16

Avastin

Roche

Preclinical

17

Winrevair

Merck & Co.

Preclinical

—8

Alphagan

AbbVie

Preclinical

—9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

210

Nipride

EExela Pharma Sciences, LLC.

Preclinical

1Show 23 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Essential Hypertension3 trials

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

Completed·Hanmi Pharmaceutical Company Limited·Phase 3·NCT05362110·361 enrolled

A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

Completed·Hanmi Pharmaceutical Company Limited·Phase 3·NCT06438172·249 enrolled

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

Completed·Hanmi Pharmaceutical Company Limited·Phase 2·NCT04959305·245 enrolled

Hypertension1 trial

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Not yet recruiting·Hanmi Pharmaceutical Company Limited·Phase 3·NCT07660796·256 enrolled

Unspecified1 trial

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

Completed·Hanmi Pharmaceutical Company Limited·Phase 1·NCT05723549·20 enrolled

Details

Drug Info

Related News